The Norwegian Tenecteplase Stroke Trial 2
Stopped Per protocol safety analysis 200 patients showed a significant difference in bleeding rates between the two drug groups.
Conditions
- Stroke, Acute
- Cerebrovascular Disorders
- Ischemic Stroke
Interventions
- DRUG: Tenecteplase
- DRUG: Alteplase
Sponsor
Haukeland University Hospital